Publikationsserver der Universitätsbibliothek Marburg
Titel:Functional Characterization of the BCR/JAK2 Fusion Gene in a Murine Pro B Cell Line
Autor:Marbach, Felix
Weitere Beteiligte: Bohlander, Stefan (Prof. Dr.)
Veröffentlicht:2015
URI:https://archiv.ub.uni-marburg.de/diss/z2015/0626
URN: urn:nbn:de:hebis:04-z2015-06269
DOI: https://doi.org/10.17192/z2015.0626
DDC: Medizin
Titel (trans.):Funktionelle Charakterisierung des BCR/JAK2 Fusionsgens in einer murinen Pro-B-Zell-Linie.
Publikationsdatum:2015-12-16
Lizenz:https://rightsstatements.org/vocab/InC-NC/1.0/

Dokument

Schlagwörter:
Fusion gene, Translokation, Leukämie, Tumor, Klonierung, Fusionsgen, Tyrosine kinase inhibitor, Protein-Tyrosin-Kinasen, Onkogen, Tyrosinkinase-Inhibitor, Mutation

Summary:
Functional description of the BCR/JAK2 fusion gene, which has been described in a patient suffering from chronic myeloid leukaemia in 2005. The T(translocation)(9;22)(p24;q11.2)leads to the formation of a fusion gene which incorporates critical regions of the breakpoint cluster region- as well as the janus kinase 2 gene. A combination of the coiled-coil dimerization domain of BCR and the JH1 tyrosine kinase domain of JAK2 generates a tumouringenic fusion protein capable of inducing Il-3 independent proliferation in an IL-3 dependent cell line.

Bibliographie / References

  1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996 May;2(5):561-6.
  2. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol. 2012 Nov 20;30(33):4161-7. doi: 10.1200/JCO.2012.42.5223. Epub 2012 Sep 10.
  3. Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB. A randomized, placebo- controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.J Clin Pharmacol. 2014
  4. Tirado CA, Chen W, Huang LJ, Laborde C, Hiemenz MC, Valdez F, et al. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia.Leuk Res. 2010;34(12):1674-6.
  5. Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva H, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Mulligan C, Lee FY, Woolfson A, Lasho TL, Pardanani A, Tefferi A, Lorenzi MV. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.Leukemia. 2012 Feb;26(2):280-8.
  6. Shimizu S, Shinohara Y, Tsujimoto Y. Bax and Bcl-xL independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene. 2000 Sep 7;19(38):4309-18.
  7. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 2001 Jan;14(1):27-37.
  8. Lane SW, Fairbairn DJ, McCarthy C, Nandini A, Perry-Keene J, Kennedy GA. Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCR-JAK2 fusion.Br J Haematol. 2008 Aug;142(4):503.
  9. Patnaik MM, Knudson RA, Gangat N, Hanson CA, Pardanani A, Tefferi A, Ketterling RP. Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates. Eur J Haematol. 2010 Jun;84(6):518-24.
  10. Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol. 2012 Dec;3(6):341- 54.
  11. Cuesta-Domínguez Á, Ortega M, Ormazábal C, Santos-Roncero M, Galán-Díez M, Steegmann JL, Figuera Á, Arranz E, Vizmanos JL, Bueren JA, Río P, Fernández-Ruiz E. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One. 2012;7(2):e32451.
  12. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005 Apr 28;434(7037):1144-8.
  13. Green MR, Sambrook S. Molecular Cloning: A Laboratory Manual (Third Edition), CSHL Press 2001
  14. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, Tapper W, Score J, Waghorn K, Naumann N, Jawhar M, Fabarius A, Hofmann WK, Cross NC, Reiter A. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.Ann Hematol. 2014 Sep 27.
  15. Heim S, Mitelman F. Cancer cytogenetics third edition. Wiley-Blackwell 2009.
  16. Liu CB, Itoh T, Arai K, Watanabe S. Constitutive activation of JAK2 confers murine interleukin-3- independent survival and proliferation of BA/F3 cells. J Biol Chem. 1999 Mar 5;274(10):6342- 9.
  17. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003 Mar 21;112(6):831-43.
  18. Wagner C, Müller O. Molekulare Onkologie -Entstehung, Progression, Klinische Aspekte, 3. Auflage. Georg Thieme Verlag 2010.
  19. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome- positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51.
  20. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007 Mar 1;6(5):550-66.
  21. Sokal et al. Prospective confirmation of a prognostic classification for Ph+ chronic myeloid leukaemia. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol. 1988 Aug;69(4):463-6.
  22. Alison MR. The cancer handbook second edition. Wiley 2007.
  23. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993 Dec; 13(12): 7587–7595.
  24. Basham B, Sathe M, Grein J, McClanahan T, D'Andrea A, Lees E, Rascle A. In vivo identification of novel STAT5 target genes. Nucleic Acids Res. 2008 Jun;36(11):3802-18.
  25. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997 Oct 1;90(7):2535-40.
  26. Elnaggar MM, Agersborg S, Sahoo T, Girgin A, Ma W, Rakkhit R, Zorrilla I, Leal A. BCR-JAK2 fusion as a result of a translocation (9;22)(p24;q11.2) in a patient with CML-like myeloproliferative disease. MolCytogenet. 2012 May 1;5(1):23.
  27. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.Nature. 1983 Nov 17-23;306(5940):239-42
  28. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpas M, Trujillo JM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987 Feb 12-18;325(6105):631-5.
  29. NCBI Gene. ABL proto-oncogene 1, non-receptor tyrosine kinase [ Homo sapiens (human) ], Gene ID: 25, updated on 3-Aug-2014. http://www.ncbi.nlm.nih.gov/gene/25
  30. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui A L, Kitamura T. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J. Sep 1, 1999; 18(17): 4754–4765.
  31. Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43.
  32. Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C, Shen W, Strelow JM, Halstead C, Rempala ME, Parthasarathy S, Gillig JR, Heinz LJ, Pei H, Wang Y, Stancato LF, Dowless MS, Iversen PW, Burkholder TP. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109.
  33. Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K.Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.Blood Cancer J. 2014 Jan 10;4:e174.
  34. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr 28;352(17):1779-90.
  35. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006 Dec 7;355(23):2408-17.
  36. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett. 2000 Jan 21;466(1):6-10.
  37. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19- 25;365(9464):1054-61.
  38. Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, Bacigalupo A, Ravazzolo R, Ballestrero A, Sessarego M. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet. 2008 Jun;183(2):105-8.
  39. de Alboran IM, O'Hagan RC, Gärtner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. Jan 2001 14(1): 45–55.
  40. Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005 Apr;37(4):726-30.
  41. Bellesso M, Santucci R, Dias DF, Centrone R, Elias RC. Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. Rev Bras Hematol Hemoter. 2013;35(3):218-9.

* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten
© UB Marburg 1997 - 2024 Universitätsbibliothek Marburg